Immediate Impact
61 standout
Citing Papers
Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements
2024 Standout
Drug resistance in ovarian cancer: from mechanism to clinical trial
2024 Standout
Works of Rita Ceccherini being referenced
Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).
2022
The Extracellular Matrix Influences Ovarian Carcinoma Cells’ Sensitivity to Cisplatinum: A First Step towards Personalized Medicine
2020
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Rita Ceccherini | 179 | 163 | 43 | 55 | 15 | 267 | |
| Blanca Munárriz | 162 | 183 | 74 | 46 | 10 | 289 | |
| Fiorita Poulakaki | 108 | 85 | 30 | 60 | 17 | 231 | |
| R. Wolters | 188 | 185 | 69 | 26 | 14 | 325 | |
| Katja Krauss | 111 | 84 | 65 | 19 | 14 | 241 | |
| Michele M. Gage | 131 | 81 | 102 | 54 | 17 | 253 | |
| Audrey Monneur | 138 | 97 | 75 | 25 | 20 | 244 | |
| WM Gregory | 193 | 101 | 57 | 52 | 16 | 314 | |
| Adher Alsayed | 163 | 107 | 33 | 29 | 18 | 291 | |
| Silvia Ruscelli | 242 | 79 | 67 | 38 | 15 | 300 | |
| K Kjellgren | 195 | 180 | 65 | 17 | 16 | 311 |
All Works
Loading papers...